Taho Pharmaceuticals Ltd.
↗Taipei, Taiwan
Taho Pharmaceuticals is a Taiwan-based specialty pharmaceutical company founded in 2010. The company focuses on developing innovative drug delivery systems, specifically proprietary Transepithelial Delivery Systems (TDS), which include transdermal patches and transmucosal oral dissolving films (ODFs).
By leveraging these delivery platforms, Taho aims to improve the administration, safety, and efficacy of existing small-molecule drugs. Their pipeline targets therapeutic areas including CNS, cardiovascular, oncology support, and opioid addiction/overdose, with a strategy of bridging the gap in current treatment options for underserved patient populations.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2010
Ownership:public
Status:operating
FUNDING
Stage:Pre-IPO/Public
Investors:Powerchip Semiconductor Manufacturing Corporation, SBI Holdings
STOCK
Exchange:Taipei Exchange
Ticker:6467
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3 (TAH3311)
Modalities:Small molecule, Transdermal delivery, Transmucosal delivery
Active Trials:1
Trial Phases:Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Global pharmaceutical collaborators (unspecified)
COMPETITION
Position:Emerging
Competitors:Alector, Synthego, Avidity Biosciences
LEADERSHIP
Key Executives:
Howard Lee - Chairman and CEO
LINKS
Website:tahopharma.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Taho Pharmaceuticals Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Taho Pharmaceuticals Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.